The evidence linking kratom to kidney injury is thinner than the evidence for liver injury — but it is not zero, and it is growing. This article describes what the case report literature shows, what the proposed mechanisms are, which symptoms warrant medical attention, and what the risk factors look like based on the available data.
The right starting frame: emerging case reports suggest a possible association between kratom and kidney injury in some users. This is not an established cause-effect relationship with a defined incidence rate. It is a signal that warrants awareness and appropriate monitoring — not alarm, and not dismissal.
TL;DR: Case reports of kratom-associated kidney injury have appeared in the medical literature, and the FDA's adverse event database includes renal-related reports. The evidence base is significantly thinner than for kratom hepatotoxicity (liver injury). Proposed mechanisms include direct alkaloid toxicity on kidney tubular cells and immune-mediated injury. Concurrent use of NSAIDs (non-steroidal anti-inflammatories like ibuprofen) is the most practically significant risk amplifier. Symptoms that warrant same-day medical attention: significantly reduced urine output, swelling in legs or ankles, or persistent lower back pain. Most documented cases resolved with kratom cessation.
What does the evidence actually show?
The kratom nephrotoxicity literature consists primarily of case reports and FDA adverse event submissions — not controlled studies. This is an important distinction: case reports describe what happened to individuals, but cannot establish the rate at which it occurs in the general kratom-using population, or whether kratom was definitively the cause.
Nelsen et al. (2010), one of the early systematic reviews of kratom toxicity cases (Journal of Medical Toxicology), documented a range of adverse events including renal-related findings. The evidence at that point was sparse.
FDA adverse event reports: The FDA's Center for Food Safety and Applied Nutrition (CFSAN) adverse event reporting system has received reports of kratom-associated kidney injury. The FDA has referenced renal effects in its kratom safety communications.
PubMed case reports (2015 onward): Individual case reports of kratom-associated acute kidney injury have appeared in the nephrology literature, predominantly describing acute tubular injury patterns in heavy long-term users.
The kidney injury evidence contrasts with the liver injury evidence in an important way: kratom's hepatotoxicity has a well-characterized pattern (cholestatic hepatitis), systematic case series review (Teschke et al. 2016), and a dedicated NIH LiverTox entry. Kratom nephrotoxicity is less characterized, lacks a systematic review, and does not yet have a LiverTox kidney-equivalent entry. The signal is real but earlier-stage.
How might kratom affect the kidneys? Proposed mechanisms
The exact mechanism of kratom-associated kidney injury is not established. Two pathways have been proposed in the case literature:
Direct tubular toxicity. The kidney's tubular cells — responsible for filtering and reabsorbing substances from the bloodstream — are exposed to high concentrations of any compound that is renally cleared. Kratom's alkaloids (mitragynine and 7-hydroxymitragynine / 7-OH) are partially renally excreted. At high doses, direct toxic effects on tubular cells are plausible, consistent with the acute tubular injury pattern seen in some case reports.
Immune-mediated injury. Some herbal compound nephrotoxicity involves immune-mediated mechanisms — the body mounts an immune response to a compound or its metabolites, producing kidney inflammation. This is a less characterized pathway for kratom specifically, but is a recognized mechanism for other herbal nephrotoxicity cases.
A note on the aristolochic acid comparison: aristolochic acid nephropathy is the archetypal herbal kidney injury — severe, progressive, and associated with specific Traditional Chinese herbal preparations. It is referenced in the herbal nephrotoxicity literature to explain how plant compounds can cause kidney injury. Kratom is chemically unrelated to aristolochic acid, and there is no basis for claiming kratom causes the same syndrome. The comparison is useful only for explaining why herbal nephrotoxicity as a category is clinically plausible; the specific mechanisms and prognosis are different.
Symptoms that warrant medical attention
If you are using kratom and notice any of the following, contact a doctor the same day — these can indicate kidney stress and warrant a renal function panel (blood urea nitrogen / BUN, creatinine, glomerular filtration rate / GFR):
- Significantly reduced urine output — notably less urine than usual, or no urine for an extended period
- Swelling in legs, ankles, or feet — edema from fluid retention is a sign of impaired kidney clearance
- Persistent lower back pain — kidney pain (distinct from muscular pain) is located in the flanks, below the rib cage; it is dull and persistent rather than movement-related
Additionally, if you are experiencing fatigue, nausea, and loss of appetite in combination — not explained by kratom withdrawal if you have stopped — these warrant a conversation with a doctor, as they can reflect impaired kidney function.
You do not need all of these symptoms to warrant a check. One is enough to justify a blood test.
Who is most at risk?
Based on the available case reports, the following factors appear associated with higher risk. As with the liver injury evidence, the data is not sufficient to establish a precise threshold.
Concurrent NSAID use. This is the most practically significant risk factor identified in the case literature. Non-steroidal anti-inflammatory drugs — ibuprofen (Advil, Motrin), naproxen (Aleve), and others — are nephrotoxic at high doses or with prolonged use. They reduce blood flow to the kidneys by inhibiting prostaglandin synthesis. Combined with any additional nephrotoxic burden, NSAIDs create a compounded risk. Many kratom users take ibuprofen for kratom-related muscle aches and headaches — this combination warrants specific caution.
High dose and long duration. Consistent with the liver injury pattern, higher alkaloid loads over longer periods are associated with greater risk. The exact dose and duration thresholds are not established in the kratom-specific literature.
Pre-existing kidney conditions. Reduced kidney function — from diabetic nephropathy, hypertension-related kidney disease, or other causes — reduces the margin for additional nephrotoxic load.
Dehydration. Dehydration reduces renal blood flow and concentrates nephrotoxic compounds in the tubular system. Kratom users who are chronically dehydrated (common given kratom's diuretic-adjacent effects and its use for athletic performance) face a compounded risk.
Concurrent alcohol use. Alcohol affects kidney function through multiple mechanisms; combined use adds to the renal burden.
What does stopping kratom do for kidney function?
In the documented cases of kratom-associated kidney injury, most resolved with kratom cessation — consistent with the pattern for drug-induced kidney injury from other herbal compounds. The kidney has significant regenerative capacity, particularly in acute tubular injury that has not progressed to chronic structural damage.
What is not established: the rate of full recovery versus partial recovery, or the rate at which kratom-associated kidney injury progresses if use continues. Case report data cannot answer these questions reliably.
The practical implication: if kidney injury is identified, stopping kratom is the primary intervention. Medical management of the kidney injury (fluid balance, blood pressure management, monitoring) may be needed depending on severity.
If you are concerned about kidney symptoms during or after kratom use, see a doctor. A renal function panel is a routine blood test. findtreatment.gov lists providers experienced in kratom cessation who can coordinate care with primary care or nephrology as needed.
Coach Aria is a 12-week behavioral coaching program for kratom recovery. The program covers the behavioral and psychological arc of cessation. For medical concerns during or after kratom use, your healthcare provider is the essential first stop. Private, no meetings, runs at your pace.